CYTK Earnings Prediction
The chart below shows how CYTK performed 10 days before and after its earnings report, based on data from the past quarters. Typically, CYTK sees a -0.50% change in stock price 10 days leading up to the earnings, and a -4.69% change 10 days following the report. On the earnings day itself, the stock moves by +1.45%. This data can give you a slight idea of what to expect for the next quarter's release.
CYTK Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
463.00K
22.49%
85.94%
Gross Margin
--
--
--
Operating Margin
-30410.58%
-5.98%
-41.83%
Net Margin
-34674.95%
1.27%
-39.76%
EPS
-1.36
-0.74%
3.82%
No Data Available
CYTK Earnings Analysis
Cytokinetics Inc. Corporation (CYTK.O) Earnings Conference Call
Positive
New Drug Application Milestone: Cytokinetics completed the rolling submission of a new drug application for aficamten to the FDA, marking a significant milestone for the company and the patient community.
Revenue Increase Q3 2024: The company reported total revenues of $0.5 million for Q3 2024, an increase from $0.4 million in the same period in 2023, indicating growth in revenue generation.
R&D Expense Increase: R&D expenses increased to $84.6 million in Q3 2024 from $82.5 million in Q3 2023, reflecting the company's commitment to advancing its pipeline.
Global Clinical Trial Expansion: Cytokinetics has activated over 90 sites in 13 countries for its clinical trials, ensuring broad representation and diversity in its study populations.
MAPLE-HCM Trial Results Expected: The company expects to share results from the MAPLE-HCM trial in the first half of 2025, which could provide valuable insights into the efficacy of aficamten.
Negative
Cash and Investments Decline: Cash, cash equivalents and investments declined by approximately $81 million during the third quarter of 2024.
Quarterly Revenue Comparison: Total revenues in the third quarter of 2024 were $0.5 million compared to $0.4 million for the same period in 2023.
R&D Expense Comparison: R&D expenses in the third quarter of 2024 were $84.6 million compared to $82.5 million for the same period in 2023.
G&A Expense Increase: G&A expenses in the third quarter of 2024 were $56.7 million compared to $40.1 million for the same period in 2023.
Quarterly Net Loss Comparison: Net loss for the second quarter of 2024 was $160.5 million or $1.36 per share basic and diluted compared to a net loss of $129.4 million or $1.35 per share basic and diluted for the same period in 2023.
CYTK FAQs
How does CYTK typically perform around its earnings report dates?
Is Cytokinetics, Incorporated (CYTK) Q3 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
CYTK Earning Call Sentiment
Cytokinetics, Incorporated (CYTK) Q3 2024 Earnings Call Transcript
1.0x
00:00
00:00
CYTK.O
0.17%Positive
The earnings call reflects mixed signals. Financial performance shows increased expenses and net loss, though cash reserves remain strong. Product development is promising with ongoing trials, but lack of clear guidance on trial outcomes and pricing strategy creates uncertainty. The Q&A session highlights management's evasiveness on critical metrics, raising concerns. Overall, the neutral sentiment stems from strong cash positioning and potential future developments, balanced by current financial challenges and unclear guidance.
